

Supplementary Appendix

Supplementary Methods

Study Design

A test negative case control design was used to estimate vaccine effectiveness against symptomatic COVID-19 with the Omicron variant compared to the Delta variant in individuals aged 18 years and older. The odds of vaccination in symptomatic PCR positive cases was compared to the odds of vaccination in symptomatic individuals who tested negative for SARS-CoV-2 in England.

Data Sources

COVID-19 Testing Data

SARS-CoV-2 Testing PCR testing for SARS CoV-2 in England is undertaken by hospital and public health laboratories (Pillar 1), as well as by community testing (Pillar 2). Pillar 2 testing is available to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste), anyone who is a contact of a confirmed case, care home staff and residents, and to those who have self-tested as positive using a lateral flow test (LFT). Data on all positive PCR and LFTs, and on negative Pillar 2 PCR tests from symptomatic individuals with a test date after 25 November 2020 were extracted up to 17 February 2022. Individuals who reported symptoms and were tested in Pillar 2 between 17 January 2022 and 17 February 2022 were included in the analysis (Supplementary Figure 1). Any negative tests taken within 7 days of a previous negative test, and any negative tests where symptom onset date was within the 10 days or a previous symptoms onset date for a negative test were dropped as these likely represent the same episode. Negative tests taken within 21 days of a subsequent positive test were also excluded as chances are high that these are false negatives. Positive and negative tests within 90 days of a previous positive test were also excluded; however, where participants had later positive tests within 14 days of a positive then preference was given to PCR tests and symptomatic tests. For individuals who had more than one negative test, one was selected at random in the study period. Data were restricted to persons who had reported symptoms and gave a symptom onset date within the 10 days before testing to account for reduced PCR sensitivity beyond this period in an infection event.

Vaccination Data

The National Immunization Management System (NIMS) contains demographic information on the whole population of England who are registered with a general practice physician in England and is used to record all COVID-19 vaccinations. NIMS was accessed for dates of vaccination and manufacturer, sex, date of birth, ethnicity, and residential address. Addresses were used to determine index of multiple deprivation quintile and were also linked to Care Quality Commission registered care homes using the unique property reference number. Data on geography (NHS region), risk group status, clinically extremely vulnerable status, and health/social care worker were also extracted from the NIMS. Clinical risk groups included a range of chronic conditions as described in the Green Book, whereas the clinically extremely vulnerable group included persons who were considered to be at the highest risk for severe COVID-19, including those with immunosuppressed conditions and those with severe respiratory disease. Booster doses were identified as a third dose given at least 84 days after a second dose and administered after 13 September 2021. Individuals

with four or more doses of vaccine, heterologous primary schedule or fewer than 19 days between their first and second dose were excluded.

Testing data were linked to NIMS on 8 February 2021 using combinations of the unique individual National Health Service (NHS) number, date of birth, surname, first name, and postcode using deterministic linkage – 99.6% of eligible tests could be linked to the NIMS.

Identification of Delta and Omicron Variants and assignment to cases

Sequencing of PCR positive samples is undertaken through a network of laboratories, including the Wellcome Sanger Institute. Whole-genome sequences are assigned to UKHSA definitions of variants based on mutations. S-gene target status on PCR-testing is an alternative approach for identifying each sub-lineage because BA.1 has been associated with S-gene target failure on PCR testing with the Taqpath assay while BA.2 has been associated with a positive S-gene target. Cases were defined as BA.1 or BA.2 based on whole genome sequencing or S-gene target status, with sequencing taking priority. Where subsequent positive tests within 14 days included sequencing or S-gene target failure information, this information was used to classify the variant.

Statistical Analysis

Logistic regression was used, with the PCR test result as the dependent variable and cases being those testing positive (stratified in separate analyses as either BA.1 or BA.2) and controls being those testing negative. Vaccination status was included as an independent variable and effectiveness defined as 1- odds of vaccination in cases/odds of vaccination in controls.


Vaccine effectiveness was adjusted in logistic regression models for age (ages 18-19, then 20 through to 89 in five-year bands, then everyone age 90 years or older), sex, index of multiple deprivation (quintile), ethnic group, history of travel, geographic region (NHS region), period (week of test), health and social care worker status, clinical risk group status, clinically extremely vulnerable, and previously testing positive. These factors were all considered potential confounders so were included in all models.

Analysis combined all vaccine manufacturers (ChAdOx1, BNT162b2 or mRNA-1273 for one dose or two doses, and BNT162b2 or mRNA-1273 (half-dose) for booster doses). Heterologous primary schedules and ChAdOx1 primary course followed by ChAdOx1 booster dose recipients were excluded.

Vaccine effectiveness was assessed in intervals of <4 weeks and 4+ weeks post the first dose; <2 weeks, 2-24 and 25+ weeks post the second dose; and < 1 week, 1, 2-4, 5-9, 10-14 and 15+ weeks post a booster dose.

Supplementary Tables and Figures

Supplementary Figure 1.



Supplementary Table 1

			Overall		Negative		BA.1		BA.2	
			n	%	n	%	n	%	n	%
			626,148	100.0%	380,739	60.8%	214,171	34.2%	31,238	5.0%
		Interval (weeks)								
		Test Result								
Vaccination Status and intervals after vaccine	Unvaccinated		56,656	9.0%	23,839	6.3%	28,589	13.3%	4,228	13.5%
	Dose 1*	<4	3,048	0.5%	1,754	0.5%	1,147	0.5%	147	0.5%
		4+	16,503	2.6%	9,155	2.4%	6,422	3.0%	926	3.0%
	Dose 2*	<2	1,331	0.2%	900	0.2%	392	0.2%	39	0.1%
		2-24	55,941	8.9%	30,431	8.0%	22,649	10.6%	2,861	9.2%
		25+	58,630	9.4%	27,191	7.1%	27,676	12.9%	3,763	12.0%
	Booster**	<1	4,189	0.7%	2,375	0.6%	1,681	0.8%	133	0.4%
		1	7,074	1.1%	5,009	1.3%	1,917	0.9%	148	0.5%
		2-4	71,415	11.4%	50,272	13.2%	19,690	9.2%	1,453	4.7%
		5-9	211,960	33.9%	144,591	38.0%	57,939	27.1%	9,430	30.2%
		10-14	93,988	15.0%	58,191	15.3%	30,881	14.4%	4,916	15.7%
		15+	45,413	7.3%	27,031	7.1%	15,188	7.1%	3,194	10.2%
	Age	18-19		17,575	2.8%	11,215	2.9%	5,583	2.6%	777
20-24		54,760	8.7%	33,884	8.9%	17,944	8.4%	2,932	9.4%	
25-29		72,059	11.5%	43,679	11.5%	24,504	11.4%	3,876	12.4%	
30-34		89,635	14.3%	54,422	14.3%	30,734	14.4%	4,479	14.3%	
35-39		91,105	14.6%	54,598	14.3%	32,297	15.1%	4,210	13.5%	
40-44		79,118	12.6%	46,998	12.3%	28,137	13.1%	3,983	12.8%	
45-49		62,566	10.0%	37,779	9.9%	21,659	10.1%	3,128	10.0%	
50-54		52,447	8.4%	32,094	8.4%	17,720	8.3%	2,633	8.4%	
55-59		40,650	6.5%	24,907	6.5%	13,777	6.4%	1,966	6.3%	
60-64		27,343	4.4%	16,879	4.4%	9,125	4.3%	1,339	4.3%	
65-69		16,352	2.6%	10,440	2.7%	5,090	2.4%	822	2.6%	
70-74		11,039	1.8%	6,893	1.8%	3,632	1.7%	514	1.6%	
75-79		5,899	0.9%	3,586	0.9%	1,989	0.9%	324	1.0%	
80-84		2,955	0.5%	1,780	0.5%	1,031	0.5%	144	0.5%	
85-89		1,661	0.3%	1,033	0.3%	554	0.3%	74	0.2%	
>=90		984	0.2%	552	0.1%	395	0.2%	37	0.1%	
Gender	Female		391,984	62.6%	243,987	64.1%	129,951	60.7%	18,046	57.8%
	Male		233,066	37.2%	136,056	35.7%	83,866	39.2%	13,144	42.1%
	Missing		1,098	0.2%	696	0.2%	354	0.2%	48	0.2%
Ethnicity	African		8,588	1.4%	4,850	1.3%	3,204	1.5%	534	1.7%
	Another Asian background		10,003	1.6%	5,571	1.5%	3,574	1.7%	858	2.7%
	Another Black background		777	0.1%	430	0.1%	283	0.1%	64	0.2%
	Another ethnic background		5,121	0.8%	2,976	0.8%	1,780	0.8%	365	1.2%
	Arab		2,930	0.5%	1,689	0.4%	1,085	0.5%	156	0.5%
	Bangladeshi		5,073	0.8%	2,726	0.7%	1,911	0.9%	436	1.4%
	Caribbean		4,283	0.7%	2,162	0.6%	1,783	0.8%	338	1.1%
	Chinese		5,594	0.9%	3,446	0.9%	1,763	0.8%	385	1.2%
	Indian		25,234	4.0%	15,457	4.1%	7,942	3.7%	1,835	5.9%

	Mixed or multiple ethnicities	11,849	1.9%	6,996	1.8%	4,144	1.9%	709	2.3%
	Pakistani	15,750	2.5%	8,239	2.2%	6,901	3.2%	610	2.0%
	Prefer not to say	25,081	4.0%	14,651	3.8%	9,041	4.2%	1,389	4.4%
	White	505,864	80.8%	311,546	81.8%	170,759	79.7%	23,559	75.4%
	Missing	1	0.0%	0	0.0%	1	0.0%	0	0.0%
NHS Region	East of England	86,213	13.8%	48,723	12.8%	31,696	14.8%	5,794	18.5%
	London	91,746	14.7%	51,270	13.5%	31,490	14.7%	8,986	28.8%
	Midlands	113,031	18.1%	69,172	18.2%	39,406	18.4%	4,453	14.3%
	North East	98,992	15.8%	55,615	14.6%	41,025	19.2%	2,352	7.5%
	North West	80,926	12.9%	42,000	11.0%	36,217	16.9%	2,709	8.7%
	South East	95,901	15.3%	67,967	17.9%	22,939	10.7%	4,995	16.0%
	South West	59,336	9.5%	45,989	12.1%	11,398	5.3%	1,949	6.2%
	Missing	3	0.0%	3	0.0%	0	0.0%	0	0.0%
IMD Quintiles	1	116,174	18.6%	61,786	16.2%	49,562	23.1%	4,826	15.4%
	2	124,346	19.9%	73,002	19.2%	44,635	20.8%	6,709	21.5%
	3	127,673	20.4%	78,564	20.6%	42,226	19.7%	6,883	22.0%
	4	128,056	20.5%	81,392	21.4%	40,121	18.7%	6,543	20.9%
	5	127,664	20.4%	84,661	22.2%	36,869	17.2%	6,134	19.6%
	Missing	2,235	0.4%	1,334	0.4%	758	0.4%	143	0.5%
Vaccine priority groups	HSCW	50,363	8.0%	31,964	8.4%	16,057	7.5%	2,342	7.5%
	At risk***	125,427	20.0%	76,330	20.0%	43,411	20.3%	5,686	18.2%
	CEV	40,342	6.4%	22,638	5.9%	15,579	7.3%	2,125	6.8%
Previously positive	No	522,920	83.5%	306,122	80.4%	189,168	88.3%	27,630	88.4%
	Yes	103,228	16.5%	74,617	19.6%	25,003	11.7%	3,608	11.6%

*Dose 1 and 2 is recipients of ChAdOx1-S, BNT162b2 or mRNA-1273.

**Booster is recipients of BNT162b2 or mRNA-1273 following any primary immunisation course.

***At risk is only those under 65

Supplementary Table 2

Doses	Interval (weeks)	Controls	BA.1		BA.2	
			Cases	VE (95% CI)	Cases	VE (95% CI)
Unvaccinated		23,839	28589	baseline	4228	baseline
Dose 1*	<4	1,754	1147	44.7 (40.1-48.9)	147	44.8 (34.0-53.9)
	4+	9,155	6422	40.7 (38.4-42.9)	926	43.0 (38.3-47.4)
Dose 2*	<2	900	392	63.6 (58.8-67.8)	39	67.1 (54.2-76.3)
	2-24	30,431	22649	36.8 (35.1-38.4)	2861	40.7 (37.5-43.8)
	25+	27,191	27676	17.4 (15.2-19.4)	3763	24.3 (20.3-28.0)
Booster**	<1	2,375	1681	46.1 (42.4-49.7)	133	52.3 (42.6-60.3)
	1	5,009	1917	71.3 (69.6-72.9)	148	72.2 (67.0-76.5)
	2-4	50,272	19690	70.2 (69.5-71.0)	1453	74.2 (72.4-75.8)
	5-9	144591	57939	66.2 (65.5-66.9)	9430	68.1 (66.7-69.5)
	10-14	58191	30881	54.3 (53.1-55.5)	4916	58.6 (56.4-60.7)
	15+	27031	15188	45.5 (43.8-47.2)	3194	48.4 (45.2-51.4)

*Dose 1 and 2 is recipients of ChAdOx1-S, BNT162b2 or mRNA-1273.

**Booster is recipients of BNT162b2 or mRNA-1273 following any primary immunisation course.